Mink Therapeutics Inc Total Assets
Mink Therapeutics Inc total assets. Based on the latest financial reports, Mink Therapeutics Inc (INKT) holds total assets worth $9.62 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see INKT market cap for the company's overall valuation and market capitalisation.
Total Assets of Mink Therapeutics Inc (2019–2025)
Total assets of Mink Therapeutics Inc from 2019 to 2025. This chart illustrates how Mink Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See INKT stock price and chart for real-time trading data and today's change.
Mink Therapeutics Inc - Asset Composition Analysis
Mink Therapeutics Inc Total Assets Breakdown (December 2025)
Mink Therapeutics Inc total assets breakdown as of December 2025. Mink Therapeutics Inc's total assets of $9.62 Million consist of 97.3% current assets and 2.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Mink Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Mink Therapeutics Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mink Therapeutics Inc's current assets represent 97.3% of total assets in 2025, an increase from 70.2% in 2019.
- Cash Position: Cash and equivalents constituted 93.8% of total assets in 2025, up from 22.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Mink Therapeutics Inc Competitors by Total Assets
Key competitors of Mink Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Mink Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.23 | 0.15 | 0.01 |
| Quick Ratio | 1.23 | 0.15 | -0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.73 Million | $-11.15 Million | $-79.68 Million |
Mink Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Mink Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.33 |
| Latest Market Cap to Assets Ratio | 3.87 |
| Asset Growth Rate (YoY) | 148.9% |
| Total Assets | $14.24 Million |
| Market Capitalization | $55.06 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Mink Therapeutics Inc's assets at a significant premium (3.87x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Mink Therapeutics Inc's assets grew by 148.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Mink Therapeutics Inc (2019–2025)
The table below shows the annual total assets of Mink Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $14.24 Million | +148.90% |
| 2024-12-31 | $5.72 Million | +25.67% |
| 2023-12-31 | $4.55 Million | -78.80% |
| 2022-12-31 | $21.47 Million | -46.64% |
| 2021-12-31 | $40.24 Million | +783.42% |
| 2020-12-31 | $4.56 Million | +248.01% |
| 2019-12-31 | $1.31 Million | -- |
About Mink Therapeutics Inc
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical tr… Read more